At a glance
ClinicalIndex Comparison Record- ✓Pathologically proven non-small cell lung cancer, Stage IV or recurrent
- ✓Prior systemic therapy with documented progression
- ✓Platinum-based chemotherapy or anti-PD-1/PD-L1 therapy prior experience
- ✓Adequate tumor tissue ≥20% tumor cells and ≥0.2 mm³
- ✕EGFR sensitizing mutations, EGFR T790M, ALK fusion, ROS1 rearrangement, or BRAF V600E unless progressed on targeted therapy
- ✕Bone biopsies not allowed for tissue submission
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
In Brief
A Phase 3 clinical trial evaluating Screening Platform for Previously Treated Non-Small Cell Lung Cancer. Currently recruiting, targeting 10,000 participants across 1,229 sites.
Detailed Summary
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Study Details
Timeline
Interventions
The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.